Niclas Högberg and William ‘Obi’ Greenman on Evolving Strategies in Massive Bleeding Management
Niclas Högberg, Sales Director at Cerus, reposted from William “Obi” Greenman on LinkedIn:
”MASSIVE BLEEDING – ARE WE DRIFTING APART IN STRATEGY?
In the U.S., 5-day Pathogen-Reduced Cryoprecipitated Fibrinogen Complex (PRCFC) is beginning to reshape massive transfusion practice.
As the study included concluded:
- “PRCFC is ready to dispense and provides an immediate source of fibrinogen in critically bleeding patients with significant reductions in TAT. There is an added benefit of reduced wastage.”
This evolution enables clinicians to act within minutes — moving beyond ratio-driven MTPs toward targeted, function-based hemostatic resuscitation.
Across Europe and the Nordics, focus has instead shifted toward Whole Blood (WB) for trauma and pre-hospital use.
While physiologically balanced, WB reintroduces challenges with traceability, shelf life, and pathogen safety — factors that SoHO and IVDR will soon regulate more tightly.
As Europe strengthens its blood preparedness and resilience, the key question is:
- Are we innovating forward — or reinventing the past for convenience?”
William “Obi” Greenman, Chairman and Chief Executive Officer at Cerus, shared on LinkedIn:
”The expansion of INTERCEPT Fibrinogen Complex use in large U.S. hospitals is really encouraging given the meaningful impact on immediate fibrinogen delivery in critically bleeding patients.
With >50% improvements in delivery time and reduced wastage, the efficiencies gained are real and the hospital transfusion service teams love the product and can focus their valuable time on other critical activities.”
Read the full article here.
Article: Pathogen-reduced cryoprecipitate: Early experiences and inventory management
Authors: C. B. Webb, A. Javanbakht, D. Hanna, S. G. Yates, R. Zhang, S. Afraz, R. Sarode
Stay updated on all scientific advances with Hemostasis Today.
-
Mar 3, 2026, 09:10From Fear to Freedom: Hemophilia A, Emicizumab Prophylaxis, and the Rewriting of a Childhood
-
Mar 3, 2026, 09:01Amy Owen-Wyard: A Life Should Not Have a Price Tag Attached to Its Rarity
-
Mar 3, 2026, 08:54Kanishk Kumar: Novel Complement Inhibitors and Next-Generation Therapies as Driving Momentum for aHUS
-
Mar 3, 2026, 08:48Megan Adediran: Redefining Rare Diseases in Nigeria’s Healthcare System
-
Mar 3, 2026, 08:18Peter Zdziarski: A Brighter Future for Glanzmann Thrombasthenia Through Gene Therapy
-
Mar 2, 2026, 17:22Hematologists and Oncologists Recognize Their Role in Specialized VA Care Despite Ongoing Knowledge Gaps – JTH
-
Mar 2, 2026, 17:04Fernando Corrales-Medina: An Evidence-Based Platform Promoting Early Recognition and Evaluation of VWD
-
Mar 2, 2026, 16:56Mbunya S. Misiani: Changing the Narrative on Bleeding Disorders Across Africa
-
Mar 2, 2026, 16:51Ofoke Chiamaka: Rehabilitation Is Not Just Muscle Training, It Is Brain Retraining